StockNow
Log in
U.S. Markets

Regeneron (REGN) exec says it expects to price obesity drug reasonably close to parity with therapies that do not offer cholesterol lowering benefits, according to remarks at a TD Cowen conference

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYU.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)

Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement